rs80357669
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_007294.4(BRCA1):c.2457del(p.Asp821IlefsTer25) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. S819S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Consequence
BRCA1
NM_007294.4 frameshift
NM_007294.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.0170
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-43093073-TG-T is Pathogenic according to our data. Variant chr17-43093073-TG-T is described in ClinVar as [Pathogenic]. Clinvar id is 37471.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr17-43093073-TG-T is described in Lovd as [Pathogenic]. Variant chr17-43093073-TG-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
|---|---|---|---|---|---|---|---|
| BRCA1 | NM_007294.4 | c.2457del | p.Asp821IlefsTer25 | frameshift_variant | 10/23 | ENST00000357654.9 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | ENST00000357654.9 | c.2457del | p.Asp821IlefsTer25 | frameshift_variant | 10/23 | 1 | NM_007294.4 | P4 |
Frequencies
GnomAD3 genomes
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250740Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135552
GnomAD3 exomes
AF:
AC:
3
AN:
250740
Hom.:
AF XY:
AC XY:
2
AN XY:
135552
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Cov.: 42
GnomAD4 exome
Cov.:
42
GnomAD4 genome
GnomAD4 genome
Cov.:
32
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:25
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:10
| Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Nov 28, 2023 | This variant deletes 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in multiple individuals and families affected with breast and ovarian cancer (PMID: 8807330, 11773283, 14760071, 16284991, 17688236, 18284688, 19340607, 22010008, 23269703, 23725378, 24504028, 24728189, 26681312, 26718727, 26845104) and colorectal cancer (PMID: 29478780). This variant has been identified in 3/250740 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Michigan Medical Genetics Laboratories, University of Michigan | Nov 03, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Nov 06, 2015 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Mar 20, 2013 | - - |
| Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Sep 08, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
| Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA1) | May 29, 2002 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 28, 2024 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Pathway Genomics | Nov 06, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | University of Washington Department of Laboratory Medicine, University of Washington | Nov 20, 2015 | - - |
not provided Pathogenic:5
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 18, 2022 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Sep 26, 2019 | PVS1, PM2, PP4, PP5 - |
| Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 01, 2023 | The BRCA1 c.2457del (p.Asp821Ilefs*25) variant alters the translational reading frame of the BRCA1 mRNA and causes the premature termination of BRCA1 protein synthesis. This variant has been reported in the published literature in individuals affected with breast and/or ovarian cancer (PMIDs: 26718727 (2016), 27836010 (2016), 27083775 (2016), 26845104 (2016), 23269703 (2013)). Based on the available information, this variant is classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 04, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 05, 2019 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Identified in individuals with BRCA1-related cancers (Couch 1996, Schorge 2001, Pal 2005, Cunningham 2014, Couch 2015); Not observed at a significant frequency in large population cohorts (Lek 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 2576delC; This variant is associated with the following publications: (PMID: 18824701, 16267036, 23725378, 23199084, 8606385, 26845104, 24728189, 26884819, 31871297, 29133208, 23269703, 29625052, 24504028, 22010008, 11606101, 20665887, 16284991, 27836010, 26718727, 25452441, 8807330, 29435075, 29478780, 29712865, 30720243, 30322717, 30309722, 26689913) - |
Hereditary breast ovarian cancer syndrome Pathogenic:4
| Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 06, 2016 | Variant summary: The BRCA1 c.2457delC (p.Asp821Ilefs) variant results in a premature termination codon, predicted to cause a truncated or absent BRCA1 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.2515delC, c.2940delA). One in silico tool predicts a damaging outcome for this variant. This variant was found in 2/121358 control chromosomes at a frequency of 0.0000165, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). This variant has been reported in numerous HBOC patients. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 28, 2016 | The p.Asp821fs variant in BRCA1 has been reported in >50 individuals with BRCA1- associated cancers (Couch 1996, Bernards 2016, Cunningham 2014, Domchek 2013, Br east Cancer Information Core (BIC), Sharing Clinical Reports Project). This vari ant has been identified in 2/66714 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs80357669). This varia nt is predicted to cause a frameshift, which alters the protein?s amino acid seq uence beginning at position 821 and leads to a premature termination codon 25 am ino acids downstream. This alteration is then predicted to lead to a truncated o r absent protein. Heterozygous loss of function of the BRCA1 gene is an establis hed disease mechanism in individuals with hereditary breast and ovarian cancer ( HBOC). In addition, this variant was classified as Pathogenic on Sep 8, 2016 by the ClinGen-approved ENIGMA expert panel (ClinVar SCV000299772.2). In summary, t his variant meets criteria to be classified as pathogenic for HBOC in an autosom al dominant manner. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change creates a premature translational stop signal (p.Asp821Ilefs*25) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is present in population databases (rs80357669, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with breast and ovarian cancer (PMID: 8807330, 23269703, 24504028, 24728189, 26681312, 26718727). This variant is also known as 2576delC, S819fs, and 819delC. ClinVar contains an entry for this variant (Variation ID: 37471). For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:3
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 27, 2022 | The c.2457delC pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 2457, causing a translational frameshift with a predicted alternate stop codon (p.D821Ifs*25). This mutation has been observed in multiple individuals with hereditary breast and ovarian cancer (HBOC) syndrome (Pal T et al. Cancer 2005 Dec;104:2807-16; Cunningham JM et al. Sci. Rep. 2014 Feb;4:4026; Song H et al. Hum. Mol. Genet. 2014 Sep;23:4703-9; Bernards SS et al. Gynecol. Oncol. 2016 Feb;140:221-5; Seifert BA et al. Clin Cancer Res, 2016 Aug;22:4087-4094; Dorling et al. N Engl J Med. 2021 02;384:428-439). In addition, in the first validated report of biallelic BRCA1 mutations, this alteration was detected in trans with a second BRCA1 mutation (p.V1736A) in a woman diagnosed with ovarian cancer at age 28 whose complex medical history also included short stature, microcephaly, developmental delay, and significant toxicity from chemotherapy (Domchek S et al. Cancer Discov. 2013 Apr;3:399-405). Of note, this alteration is also designated as 2576delC in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
| Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 18, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 20, 2023 | This variant deletes 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in multiple individuals and families affected with breast and ovarian cancer (PMID: 8807330, 11773283, 14760071, 16284991, 17688236, 18284688, 19340607, 22010008, 23269703, 23725378, 24504028, 24728189, 26681312, 26718727, 26845104, 3347199; Leiden Open Variation Database DB-ID BRCA1_003958) and colorectal cancer (PMID: 29478780). This variant has been identified in 3/250740 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Familial cancer of breast;C2676676:Breast-ovarian cancer, familial, susceptibility to, 1;C3280442:Pancreatic cancer, susceptibility to, 4;C4554406:Fanconi anemia, complementation group S Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 16, 2022 | - - |
BRCA1-related disorder Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 13, 2024 | The BRCA1 c.2457delC variant is predicted to result in a frameshift and premature protein termination (p.Asp821Ilefs*25). This variant has been reported to be causative for breast and ovarian cancer (Plummer et al. 1995.PubMed ID: 8595428; Domchek et al. 2013. PubMed ID: 23269703; Cunningham et al. 2014. PubMed ID: 24504028; AlDubayan et al. 2018. PubMed ID: 29478780; Carter et al. 2018. PubMed ID: 30322717; Soussi et al. 2019. PubMed ID: 30720243). This variant is reported in 0.0026% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant has been reported in the ClinVar database as pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/37471/). Frameshift variants in BRCA1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Fanconi anemia, complementation group S Pathogenic:1
| Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2013 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at